产品
编 号：F622045
分子式：C23H24ClFN4O3
分子量：458.91
分子式：C23H24ClFN4O3
分子量：458.91
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1801333-55-0
产品详情
生物活性：
PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction.?PF-06952229 is a promising antineoplastic?agent for the study solid tumors, especifically metastatic breast cancer.
体内研究：
PF-06952229 (oral gavage; 30 mg/kg; twice daily; 21 days) combines with Palbociclib 21 days results in an improved inhibition of pSMAD2 in the MCF7 ER+?xenograft breast cancer tumor model. This combination also leads to a significant increase in survival relative to PF-06952229 monotherapy.Animal Model:MCF-7 ER+?HER2-xenograft breast cancer tumor model
Dosage:30 mg/kg
Administration:Oral gavage; twice daily; 44 days
Result:Resulted in an increase in tumor growth inhibition when combined with Palbociclib.
PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction.?PF-06952229 is a promising antineoplastic?agent for the study solid tumors, especifically metastatic breast cancer.
体内研究：
PF-06952229 (oral gavage; 30 mg/kg; twice daily; 21 days) combines with Palbociclib 21 days results in an improved inhibition of pSMAD2 in the MCF7 ER+?xenograft breast cancer tumor model. This combination also leads to a significant increase in survival relative to PF-06952229 monotherapy.Animal Model:MCF-7 ER+?HER2-xenograft breast cancer tumor model
Dosage:30 mg/kg
Administration:Oral gavage; twice daily; 44 days
Result:Resulted in an increase in tumor growth inhibition when combined with Palbociclib.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备